Poly[bis(trifluoroethoxy)phosphazene] Particles for Biocompatibility and Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing medical particles used in diagnostic and therapeutic procedures often cause tissue irritation, adverse immune reactions, rapid degradation, and difficulties in achieving stable suspension and visualization, leading to suboptimal delivery and imaging.
Innovation Solution
Development of particles composed of poly[bis(trifluoroethoxy)phosphazene] or its derivatives, which are biocompatible, resistant to degradation, and can be formulated to minimize blood flow, deliver active agents, and enhance ultrasound imaging, while maintaining stability and visibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If prior art particles are used in medical applications, then they can be delivered to treatment sites, but they cause tissue irritation and adverse immune reactions
Solution Approach 1:
The patent changes the chemical composition parameters of the particle material from traditional polymers to polyphosphazene-based materials with specific fluorinated side chains. This parameter change fundamentally alters the biocompatibility profile, eliminating tissue irritation and immune reactions while maintaining functional performance for medical applications.
Solution Approach 2:
The invention uses composite polyphosphazene materials combining the phosphazene backbone with fluorinated side chains (such as trifluoroethoxy groups). This composite structure provides both the structural integrity needed for particle formation and the biocompatibility required to avoid adverse immune reactions, resolving the contradiction between functionality and safety.
2Duration of action of moving object
If prior art particles are used, then they can be formulated for delivery, but they degrade rapidly in the mammalian body releasing toxic compounds
Solution Approach 1:
The patent changes the chemical stability parameters by using the phosphazene backbone with fluorinated substituents. This parameter change increases resistance to hydrolysis and enzymatic degradation, allowing particles to maintain structural integrity in the mammalian body for extended periods without releasing toxic degradation products.
Solution Approach 2:
The invention creates long-lasting stable particles that do not rapidly degrade like prior art materials. The polyphosphazene structure provides sustained stability in physiological environments, eliminating the need for frequent re-administration and preventing the release of toxic compounds associated with rapid degradation of traditional polymers.
3Ease of operation
If prior art particles are incorporated into delivery suspension, then they can be injected, but they settle or float non-uniformly and aggregate
Solution Approach 1:
The patent changes the surface chemical parameters of the particles through polyphosphazene composition, which modifies surface charge and hydrophobicity. These parameter changes improve suspension stability by reducing aggregation and achieving uniform distribution in delivery solutions, eliminating settling and floating problems of prior art particles.
Solution Approach 2:
The polyphosphazene material acts as an intermediary that provides optimal interfacial properties between the particle core and the aqueous delivery medium. This intermediary composition mediates the interaction between particles and suspension medium, preventing aggregation and ensuring uniform suspension for injection.
4Object-affected harmful factors
If clear polymeric acrylate hydrogel beads are used, then they are biocompatible, but they are difficult to visualize in aqueous suspension
Solution Approach 1:
The patent changes the optical parameters of the particles by using polyphosphazene materials with fluorinated side chains that provide inherent optical contrast. This parameter change enables visualization of particles in aqueous suspension without requiring additional opaque additives, maintaining biocompatibility while improving detectability for procedural guidance.
Data Source
AI summary
Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Further, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging. The particles may include agents for increasing density for achieving useful buoyancy levels in suspension.